EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Cancer‐Specific Survival of Trimodal Therapy Versus Radical Cystectomy in T2N0M0 Non‐Urothelial Bladder Cancer

Mattia Longoni iD, Andrea Marmiroli, Fabian Falkenbach, Quynh Chi Le, Michele Nicolazzini, Calogero Catanzaro, Federico Polverino, Jordan A Goyal, Matteo Ferro, Markus Graefen, Felix K H Chun, Carlotta Palumbo und 9 weitere

Journal of Surgical Oncology · 2025

DOI: 10.1002/jso.70014 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Surgical Oncology, 2025. Verfasst von Mattia Longoni und 20 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Cystectomy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

We hypothesized that, within organ‐confined (OC, T2N0M0) non‐urothelial carcinoma of urinary bladder (non‐UCUB) patients, trimodal therapy (TMT) use does not differ from radical cystectomy (RC) regarding cancer control outcomes.

Methods

Within the SEER database (2004–2021), rates of TMT versus RC use in OC non‐UCUB patients were calculated. Nearest‐neighbor 1:1 propensity score matching (PSM) for age, sex, race/ethnicity, and histological subtype was applied. Cumulative incidence plots depicted 5‐year cancer‐specific (CSM) and other‐cause mortality (OCM) rates. Multivariable competing risks regression (CRR) models were fitted. Sensitivity analyses were performed within squamous cell (SCC), neuroendocrine (NEC), and adenocarcinoma (ADK) and other histological subtypes.

Results

Of 814 OC non‐UCUB patients, 310 (38%) received TMT versus 504 (62%) RC. After PSM, 5‐year CSM rate was 50% after TMT versus 29% after RC and TMT was associated with 2.1‐fold higher CSM relative to RC (multivariable HR [mHR]: 2.1, p < 0.001). In sensitivity analyses within 229 (28%) SCC, TMT patients had higher 5‐year CSM rates relative to their RC‐counterparts (67% vs. 22%, mHR: 4.3, p < 0.001). Similarly, within 314 (39%) NEC, TMT patients had higher 5‐year CSM rates relative to their RC‐counterparts (mHR: 1.8, p < 0.001). Conversely, within 118 (28%) ADK and 153 (19%) other subtypes, CSM after TMT did not differ from CSM after RC (33% vs. 15%, mHR: 1.4 and 43% vs. 33%, mHR: 1.4; p = 0.4).

Conclusion

In OC non‐UCUB patients TMT is associated with significantly higher CSM than RC. Most pronounced survival disadvantage was recorded within SCC and NEC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsCystectomyHumansMaleFemaleAgedMiddle AgedSEER ProgramSurvival RateCombined Modality TherapyNeoplasm StagingFollow-Up StudiesPropensity ScoreRetrospective Studies

Stichwörter der Autor:innen

bladder cancernon‐urothelialradical cystectomysubtypestrimodal therapy

Autor:innen und Institutionen

  • Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Division of Experimental Oncology/Unit of Urology; URI; IRCCS Ospedale San Raffaele, Milan, Italy.
  • Vita-Salute San Raffaele University, Milan, Italy.
  • Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy.
  • Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Urology, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany.

ORCID-Profile: Mattia Longoni

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Longoni, M., Marmiroli, A., Falkenbach, F., Le, Q. C., Nicolazzini, M., Catanzaro, C., Polverino, F., Goyal, J. A., Ferro, M., Graefen, M., Chun, F. K. H., Palumbo, C., Schiavina, R., Longo, N., Saad, F., Shariat, S. F., Moschini, M., Gandaglia, G., Montorsi, F., …, & Karakiewicz, P. I. (2025). Cancer‐Specific Survival of Trimodal Therapy Versus Radical Cystectomy in T2N0M0 Non‐Urothelial Bladder Cancer. Journal of Surgical Oncology. https://doi.org/10.1002/jso.70014

Vancouver

Longoni M, Marmiroli A, Falkenbach F, Le QC, Nicolazzini M, Catanzaro C, et al. Cancer‐Specific Survival of Trimodal Therapy Versus Radical Cystectomy in T2N0M0 Non‐Urothelial Bladder Cancer. Journal of Surgical Oncology. 2025. doi:10.1002/jso.70014

BibTeX
@article{Longoni2025,
  author = {Longoni, Mattia and Marmiroli, Andrea and Falkenbach, Fabian and Le, Quynh Chi and Nicolazzini, Michele and Catanzaro, Calogero and Polverino, Federico and Goyal, Jordan A and Ferro, Matteo and Graefen, Markus and Chun, Felix K H and Palumbo, Carlotta and Schiavina, Riccardo and Longo, Nicola and Saad, Fred and Shariat, Shahrokh F and Moschini, Marco and Gandaglia, Giorgio and Montorsi, Francesco and Briganti, Alberto and Karakiewicz, Pierre I},
  title = {Cancer‐Specific Survival of Trimodal Therapy Versus Radical Cystectomy in T2N0M0 Non‐Urothelial Bladder Cancer},
  journal = {Journal of Surgical Oncology},
  year = {2025},
  doi = {10.1002/jso.70014}
}
Kostenlos starten →